Key result
SGLT2 inhibitors reduce the risk of cardiovascular events, hospitalization, and mortality in patients with heart failure through mechanisms including volume regulation and cardiac remodeling.
Answers are grounded in this paper and cite their sources.
SGLT2 inhibitors are a foundational therapy for heart failure, providing significant cardiovascular benefits through multiple mechanisms including improved cardiac energetics and reduced pathological remodeling.
Heart failure (HF) is a worldwide pandemic that affects at least 26 million people and is becoming more prevalent. Heart failure health expenditures are substantial and will considerably increase with population aging. Newer medications for treating type 2 diabetes include sodium-glucose cotransporter-2 inhibitors (SGLT2). Recent clinical studies and research have shown the efficacy of this class in treating heart failure by lowering the risk of cardiovascular events, hospitalization, and mortality. In addition, there is undeniable evidence that SGLT2 inhibitors have a beneficial effect on metabolic function, even though the mechanisms responsible for these drugs' practical consequences have not been completely elucidated. In this narrative review, we discuss the effects of SGLT2 inhibitors on the provision of cardiac energy by ketone bodies, pathological remodeling of the ventricle, arterial stiffness, and inflammation in patients with HF.
No takes yet. Share an insight, caveat, or question.
Geavlete et al. (2023) conducted a review in Heart failure. SGLT2 inhibitors was evaluated. SGLT2 inhibitors reduce the risk of cardiovascular events, hospitalization, and mortality in patients with heart failure through mechanisms including volume regulation and cardiac remodeling.
Synapse has enriched 10 related papers. Consider them for comparative context: